Benitec Biopharma (BNTC) Surges 33% Following Full Year Financial Results
Bentic Biopharma (BNTC) is up 33% for the day, following their 2022 financial results and operational update.
“We continue to move closer to the initiation of the clinical evaluation of BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma. “The Benitec team remains committed to improving the lives of patients suffering from Oculopharyngeal Muscular Dystrophy.”
The operational update focuses on the development of BB-301 for Oculopharyngeal Muscular Dystrophy, the clinical development of which, will be conducted in France, Canada and the United States.
More information on the operational updates can be found here.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.